Glenmark defends price of its COVID-19 drug favipiravir version after DCGI sends notice

Shares of the Mumbai-based company fell as much as 5.8% on Monday after local media reports said the Drug Controller General of India (DCGI) pulled up Glenmark regarding the price of the tablet and other concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2BhkwZE
via IFTTT